ArticleAntibody therapeutics2026
Durable disease control following treatment with ALMB-0168, a novel Cx43 hemichannel agonist monoclonal antibody, in femoral osteosarcoma with lung metastases after chemotherapy failure: a case report.
Article in Antibody therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Limited progress has been made over the past three decades in improving survival for patients with osteosarcoma after standard therapy. ALMB0168 is a first-in-class therapeutic antibody agonist targeting Cx43 hemichannels and has demonstrated to suppress the growth and migration of osteosarcoma in preclinical studies. This article presents a case of a patient with bilateral femoral osteosarcoma who was treated with ALMB0168. The patient, who had metastases in both contralateral limb and lung with ≥3 prior lines chemotherapy, showed immediate lesion shrinkage upon treatment and subsequently achieved durable partial response with a long duration of the response. The patient had a progression-free survival of 23 months to date, and the treatment was still ongoing. This case highlights that ALMB0168 may represent a promising treatment option for patients with metastatic or unresectable osteosarcoma after standard chemotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.